

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**September 17, 2020**

Date of Report (Date of Earliest Event Reported)



**The Chemours Company**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction  
Of Incorporation)

**001-36794**

(Commission  
File Number)

**46-4845564**

(I.R.S. Employer  
Identification No.)

**1007 Market Street**

**Wilmington, Delaware 19801**

(Address of principal executive offices)

Registrant's telephone number, including area code: (302) 773-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of Each Class</u>	<u>Trading Symbol(s)</u>	<u>Name of Exchange on Which Registered</u>
Common Stock (\$0.01 par value)	CC	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events.**

On September 17, 2020, The Chemours Company (the “Company”) repaid the remaining \$100 million of outstanding borrowings under its five-year, \$800 million senior secured revolving credit facility (the “Facility”).

As previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on April 3, 2020, the Company had borrowed \$300 million under the Facility as a precautionary measure in light of macroeconomic uncertainties driven by the current novel coronavirus (“COVID-19”). The Company repaid \$200 million of the outstanding borrowings on August 28, 2020, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on August 31, 2020. Following the Company’s repayment of \$100 million on September 17, 2020, no borrowings remain outstanding under the Facility.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE CHEMOURS COMPANY

By: /s/ Sameer Ralhan  
Sameer Ralhan  
Senior Vice President, Chief Financial  
Officer

Date: September 17, 2020